758 related articles for article (PubMed ID: 27411302)
1. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
2. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
3. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
4. EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway.
Mo SJ; Liu X; Hao XY; Chen W; Zhang KS; Cai JP; Lai JM; Liang LJ; Yin XY
Cancer Lett; 2016 Oct; 380(2):403-412. PubMed ID: 27378242
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
6. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
[TBL] [Abstract][Full Text] [Related]
8. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.
Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M
Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381
[TBL] [Abstract][Full Text] [Related]
9. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma.
Arensman MD; Kovochich AN; Kulikauskas RM; Lay AR; Yang PT; Li X; Donahue T; Major MB; Moon RT; Chien AJ; Dawson DW
Oncogene; 2014 Feb; 33(7):899-908. PubMed ID: 23416978
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
[TBL] [Abstract][Full Text] [Related]
11. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D; Wang J; Shi X; Yue B; Hao J
Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
[TBL] [Abstract][Full Text] [Related]
12. β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer.
Eurola A; Ristimäki A; Mustonen H; Nurmi AM; Hagström J; Kallio P; Alitalo K; Haglund C; Seppänen H
Tumour Biol; 2022; 44(1):69-84. PubMed ID: 35786664
[TBL] [Abstract][Full Text] [Related]
13. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
14. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
15. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer.
Lanki MA; Seppänen HE; Mustonen HK; Böckelman C; Juuti AT; Hagström JK; Haglund CH
Tumour Biol; 2018 Sep; 40(9):1010428318801188. PubMed ID: 30246618
[TBL] [Abstract][Full Text] [Related]
17. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
18. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
19. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma.
Hu D; Ansari D; Zhou Q; Sasor A; Said Hilmersson K; Andersson R
World J Surg Oncol; 2019 Feb; 17(1):29. PubMed ID: 30736807
[TBL] [Abstract][Full Text] [Related]
20. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.
Pozios I; Knösel T; Zhao Y; Assmann G; Pozios I; Müller MH; Bruns CJ; Kreis ME; Seeliger H
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1887-1897. PubMed ID: 30046904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]